Next Dallas

Irving, Texas 75039-2743

22 studies enrolling now · 24 studies all time

What they study most

Advanced Breast Cancer, Advanced Hematologic Tumors, Advanced Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Breast Cancer, CRC, Cancer, Carcinoma, Non-Small-Cell Lung, Colo-rectal Cancer, Colorectal Cancer

Studies at this site

• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — Recruiting now
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies — Recruiting now
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Recruiting now
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — Recruiting now
• STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas — Recruiting now
• A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors — Recruiting now
• Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors — Recruiting now
• A Phase 1 Study of IM-1617 in Participants With Advanced Cancer — Recruiting now
• A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors — Recruiting now
• Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors — Recruiting now
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of HS-20110 in Participants With Advanced Solid Tumors — Recruiting now
• Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors — Recruiting now
• Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors — Recruiting now
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors — Stopped early
• BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors — Stopped early